Page 129 - Read Online

carcinoma and cholangiocarcinoma: an immunohistochemical analysis of Shimada H, Takazawa K, Tanaka M, Inokuchi S, Makuuchi H. Ubiquitous
E-cadherin, alpha-catenin and beta-catenin. Liver 2002;22:43-50. p63 expression in human esophageal squamous cell carcinoma. Int J Mol
69. Chen J, Zhao J, Ma R, Lin H, Liang X, Cai X. Prognostic significance of Med 2004;14:169-73.
e-cadherin expression in hepatocellular carcinoma: a meta-analysis. PLoS 88. Inoue K, Fry EA. Alterations of p63 and p73 in human cancers. Subcell
One 2014;9:e103952. Biochem 2014;85:17-40.
70. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J. Association 89. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D,
of E-cadherin, matrix metalloproteinases, and tissue inhibitors of Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for
metalloproteinases with the progression and metastasis of hepatocellular p63 and p73: evidence for broader tumor suppressor functions for the p53
carcinoma. Mod Pathol 2006;19:533-40. family. Cancer Cell 2005;7:363-73.
71. Schneider MR, Hiltwein F, Grill J, Blum H, Krebs S, Klanner A, 90. Iwakuma T, Lozano G, Flores ER. Li-Fraumeni syndrome: a p53 family
Bauersachs S, Bruns C, Longerich T, Horst D, Brandl L, de Toni E, Herbst affair. Cell Cycle 2005;4:865-7.
A, Kolligs FT. Evidence for a role of E-cadherin in suppressing liver 91. Zdzalik M, Pustelny K, Kedracka-Krok S, Huben K, Pecak A, Wladyka
carcinogenesis in mice and men. Carcinogenesis 2014;35:1855-62. B, Jankowski S, Dubin A, Potempa J, Dubin G. Interaction of regulators
72. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K, Berry Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle
DA, Hung MC. MDM2 promotes cell motility and invasiveness by 2010;9:4584-91.
regulating E-cadherin degradation. Mol Cell Biol 2006;26:7269-82. 92. Kadakia M, Slader C, Berberich SJ. Regulation of p63 function by Mdm2
73. Hartsough MT, Steeg PS. Nm23/nucleoside diphosphate kinase in human and MdmX. DNA Cell Biol 2001;20:321-30.
cancers. J Bioenerg Biomembr 2000;32:301-8. 93. Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden
74. Thakur RK, Yadav VK, Kumar A, Singh A, Pal K, Hoeppner L, Saha D, KH. Functional interplay between MDM2, p63/p73 and mutant p53.
Purohit G, Basundra R, Kar A, Halder R, Kumar P, Baral A, Kumar MJ, Baldi Oncogene 2015;34:4300-10.
A, Vincenzi B, Lorenzon L, Banerjee R, Kumar P, Shridhar V, Mukhopadhyay 94. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The
D, Chowdhury S. Non-metastatic 2 (NME2)-mediated suppression of lung human MDM2 oncoprotein increases the transcriptional activity and the
cancer metastasis involves transcriptional regulation of key cell adhesion factor protein level of the p53 homolog p63. J Biol Chem 2002;277:2674-81.
vinculin. Nucleic Acids Res 2014;42:11589-600. 95. Lam EW, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning
75. Miyazaki H, Fukuda M, Ishijima Y, Takagi Y, Iimura T, Negishi A, forks for transcriptional harmony. Nat Rev Cancer 2013;13:482-95.
Hirayama R, Ishikawa N, Amagasa T, Kimura N. Overexpression of 96. Xu D, He X, Chang Y, Xu C, Jiang X, Sun S, Lin J. Inhibition of miR-
nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell 96 expression reduces cell proliferation and clonogenicity of HepG2
line results in reduced metastasis, differentiated phenotype in the metastatic hepatoma cells. Oncol Rep 2013;29:653-61.
site, and growth factor-independent proliferative activity in culture. Clin 97. Arden KC. Multiple roles of FOXO transcription factors in mammalian
Cancer Res 1999;5:4301-7. cells point to multiple roles in cancer. Exp Gerontol 2006;41:709-17.
76. Thakur RK, Yadav VK, Kumar P, Chowdhury S. Mechanisms of non- 98. Yamaguchi F, Hirata Y, Akram H, Kamitori K, Dong Y, Sui L, Tokuda M.
metastatic 2 (NME2)-mediated control of metastasis across tumor types. FOXO/TXNIP pathway is involved in the suppression of hepatocellular
Naunyn Schmiedebergs Arch Pharmacol 2011;384:397-406. carcinoma growth by glutamate antagonist MK-801. BMC Cancer
77. Lee MJ, Xu DY, Li H, Yu GR, Leem SH, Chu IS, Kim IH, Kim DG. Pro- 2013;13:468.
oncogenic potential of NM23-H2 in hepatocellular carcinoma. Exp Mol 99. Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu
Med 2012;44:214-24. MC. Forkhead box transcription factor FOXO3a suppresses estrogen-
78. Iizuka N, Oka M, Noma T, Nakazawa A, Hirose K, Suzuki T. NM23-H1 dependent breast cancer cell proliferation and tumorigenesis. Breast
and NM23-H2 messenger RNA abundance in human hepatocellular Cancer Res 2008;10:R21.
carcinoma. Cancer Res 1995;55:652-7. 100. Blake DC, Jr., Mikse OR, Freeman WM, Herzog CR. FOXO3a elicits a
79. Polanski R, Maguire M, Nield PC, Jenkins RE, Park BK, Krawczynska pro-apoptotic transcription program and cellular response to human lung
K, Devling T, Ray-Sinha A, Rubbi CP, Vlatkovic N, Boyd MT. MDM2 carcinogen nicotine-derived nitrosaminoketone (NNK). Lung Cancer
interacts with NME2 (non-metastatic cells 2, protein) and suppresses 2010;67:37-47.
the ability of NME2 to negatively regulate cell motility. Carcinogenesis 101. Ni D, Ma X, Li HZ, Gao Y, Li XT, Zhang Y, Ai Q, Zhang P, Song EL,
2011;32:1133-42. Huang QB, Fan Y, Zhang X. Downregulation of FOXO3a promotes tumor
80. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews metastasis and is associated with metastasis-free survival of patients with
NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes clear cell renal cell carcinoma. Clin Cancer Res 2014;20:1779-90.
multiple products with transactivating, death-inducing, and dominant- 102. Cheng CW, Chen PM, Hsieh YH, Weng CC, Chang CW, Yao CC, Hu LY,
negative activities. Mol Cell 1998;2:305-16. Wu PE, Shen CY. Foxo3a-mediated overexpression of microRNA-622
81. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, suppresses tumor metastasis by repressing hypoxia-inducible factor-
Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, 1alpha in erk-responsive of lung cancer. Oncotarget 2015 doi: 10.18632/
Bicciato S, Balmain A, Piccolo S. A Mutant-p53/Smad complex opposes oncotarget.5826.
p63 to empower TGFbeta-induced metastasis. Cell 2009;137:87-98. 103. 103. Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G, Bu X, Cai S, Du
82. Gu X, Coates PJ, Boldrup L, Nylander K. p63 contributes to cell invasion J, He Z. FOXO3a modulates WNT/beta-catenin signaling and suppresses
and migration in squamous cell carcinoma of the head and neck. Cancer epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal
Lett 2008;263:26-34. 2015;27:510-8.
83. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting 104. Shiota M, Song Y, Yokomizo A, Kiyoshima K, Tada Y, Uchino H,
with mutant p53. Cell Death Differ 2011;18:1487-99. Uchiumi T, Inokuchi J, Oda Y, Kuroiwa K, Tatsugami K, Naito S.
84. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Foxo3a suppression of urothelial cancer invasiveness through Twist1,
Muller PA, Dötsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res
Takahashi N, Vandenabeele P, Knight RA, Levine AJ, Melino G. Loss of 2010;16:5654-63.
p63 and its microRNA-205 target results in enhanced cell migration and 105. Su B, Gao L, Baranowski C, Gillard B, Wang J, Ransom R, Ko HK,
metastasis in prostate cancer. Proc Natl Acad Sci U S A 2012;109:15312-7. Gelman IH. A genome-wide RNAi screen identifies FOXO4 as a
85. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG, Park JH, Chi metastasis-suppressor through counteracting PI3K/AKT signal pathway
SG. Frequent alteration of p63 expression in human primary bladder in prostate cancer. PLoS One 2014;9:e101411.
carcinomas. Cancer Res 2000;60:3370-4. 106. Xu MM, Mao GX, Liu J, Li JC, Huang H, Liu YF, Liu JH. Low expression
86. Spiesbach K, Tannapfel A, Mossner J, Engeland K. TAp63gamma can of the FoxO4 gene may contribute to the phenomenon of EMT in non-
substitute for p53 in inducing expression of the maspin tumor suppressor. small cell lung cancer. Asian Pac J Cancer Prev 2014;15:4013-8.
Int J Cancer 2005;114:555-62. 107. Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF,
87. Hara T, Kijima H, Yamamoto S, Kenmochi T, Kise Y, Tanaka H, Chino O, Li M, Gao ZL. Upregulator of cell proliferation predicts poor prognosis

Hepatoma Research | Volume 2 | May 6, 2016 120